Innovation. Identification. Integrity.

Real-Time Diagnostics for Modern Infectious Disease Management

Explore

The New Standard In High-Performance Clinical Diagnostics

We are the leading biotechnology firm committed to antimicrobial stewardship through high-complexity clinical diagnostics.

We improve healthcare for all by enabling the expedited delivery of targeted antimicrobial therapies the first time, every time.

We partner with the most trusted providers, healthcare systems, and insurance networks to deliver best-in-class technologies that lower costs and improve outcomes.

Next-Generation Infection Management for Patients Across Any Site of Care

  • Advanced Diagnostic Reporting in Less Than 24 Hours
  • Precision Antibiotic Resistance Markers
  • Therapy Guidance Based Upon Objective Data and Analytics
  • Lowering Costs, Improving Outcomes, Healthier Patients
Inpatient Outpatient Skilled Facilities Home Health

Introducing A Novel Approach To Antimicrobial Stewardship

The intercept PCR™ molecular diagnostics platform enables providers to order same-day and next-day diagnostic data on complicated patient conditions through non-invasive methods. intercept PCR™ also excels as a simplified integration solution that is complimentary, not competitive, to existing laboratory arrangements across any clinical setting.

High Speed

High Fidelity

STAT and Next Day results report across all testing modalities. Specificity of molecular diagnostics testing at greater than 99%. Ability to differentiate specimens which are polymicrobial compared to traditional culture.

Integrated Data

Actionable Analytics

Intercept PCR™ is the dynamic data engine behind the molecular diagnostics platform. Providers and systems gain access to a unique portal form which they can access real-world data and quantify impacts of enhanced antibiotic prescribing patterns.

Lowering Costs

Improving Outcomes

Antimicrobial stewardship is a strategic approach to antibiotic prescribing. This practice is evidence-based and paramount to delivering value-based therapy. Real-time and near-time diagnostic insights help guide earlier and more effective therapeutic intervention.

Integrity Laboratories began testing for SARS-CoV-2 (COVID-19) under Emergency Use Authorization (EUA) on March 23.

Please direct all inquiries to covid19@integritylaboratories.com for immediate review.

Explore CDC Resources   |   Explore FDA Resources